cucpt22 (MedChemExpress)
94
Structured Review
MedChemExpress
cucpt22
Cucpt22, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 20 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cucpt22/CU-CPT22/pm32120313-101-44-47
Average 94 stars, based on 20 article reviews
Cucpt22, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 20 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cucpt22/CU-CPT22/pm32120313-101-44-47
Average 94 stars, based on 20 article reviews
cucpt22 - by Bioz Stars,
2026-10
94/100 stars
Images
Related Articles
Incubation:Article Title: Cholesterol-modified DP7 enhances the effect of individualized cancer immunotherapy based on neoantigens. Article Snippet: The protein samples were probed with 250 anti-protease-activated complex subunit 2 (Psme2) (Abcam), anti-calreticulin 251 (Abcam), and anti-antigen peptide transporter 1 (Tap1) (Abcam) antibodies and then 252 incubated with a horseradish peroxidase (HRP)-conjugated secondary antibody (Cell 253 Signaling Technology). .. When pathway inhibitors were used, DCs were pretreated 254 with 50 μM MG-132 (NF-κB inhibitor) (Selleckchem, US) for 1 h, 40 μM ST2825 255 (MyD88 inhibitor) (MCE, US) for 3 h, 150 μM C29 (TLR2 inhibitor) (MCE, US) for 256 1 h, 8 μM Western Blot:Article Title: Cholesterol-modified DP7 enhances the effect of individualized cancer immunotherapy based on neoantigens. Article Snippet: The protein samples were probed with 250 anti-protease-activated complex subunit 2 (Psme2) (Abcam), anti-calreticulin 251 (Abcam), and anti-antigen peptide transporter 1 (Tap1) (Abcam) antibodies and then 252 incubated with a horseradish peroxidase (HRP)-conjugated secondary antibody (Cell 253 Signaling Technology). .. When pathway inhibitors were used, DCs were pretreated 254 with 50 μM MG-132 (NF-κB inhibitor) (Selleckchem, US) for 1 h, 40 μM ST2825 255 (MyD88 inhibitor) (MCE, US) for 3 h, 150 μM C29 (TLR2 inhibitor) (MCE, US) for 256 1 h, 8 μM |